Klee Justin's Insider Trades & SAST Disclosures
Klee Justin's most recent trade in Amylyx Pharmaceuticals Inc was a trade of 21,490 Common Stock done at an average price of $3.5 . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Klee Justin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.46 per share. | 31 Mar 2025 | 21,490 | 3,355,276 | - | 3.5 | 74,454 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 270,177 | 270,177 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 180,118 | 3,376,766 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 03 Mar 2025 | 4,595 | 3,196,648 | - | 3.2 | 14,483 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 36,310 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 05 Feb 2025 | 36,310 | 3,201,243 | - | 1.6 | 57,007 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 03 Feb 2025 | 11,855 | 3,164,933 | - | 3.5 | 41,104 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.04 per share. | 06 Jan 2025 | 7,471 | 3,176,788 | - | 4.0 | 30,202 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2024 | 63,690 | 36,310 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 04 Nov 2024 | 63,690 | 3,184,259 | - | 1.6 | 99,993 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.20 per share. | 30 Sep 2024 | 18,589 | 3,120,569 | - | 3.2 | 59,429 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 380,000 | 380,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 179,850 | 3,139,158 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 4,135 | 2,959,308 | - | 18.7 | 77,440 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Klee Justin | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 126,667 | 2,963,443 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Klee Justin | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 5,841 | 2,836,776 | - | 16.3 | 95,372 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.84 per share. | 16 Mar 2023 | 96,555 | 2,796,062 | - | 31.8 | 3,074,359 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 50,000 | 2,842,617 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.48 per share. | 16 Mar 2023 | 3,445 | 2,792,617 | - | 32.5 | 111,877 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 4,122 | 2,894,463 | - | 36.1 | 148,717 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 1,846 | 2,892,617 | - | 36.8 | 67,912 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.37 per share. | 05 May 2022 | 334,520 | 2,898,585 | - | 0.4 | 123,772 | Common Stock |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2022 | 334,520 | 0 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 337,500 | 337,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2022 | 75,000 | 2,564,065 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 0 | - | - | Series C-1 Preferred Stock | ||
| Amylyx Pharmaceuticals Inc | Justin Klee | Director, Co-Chief Executive Officer | 06 Jan 2022 | 4,870 | 2,489,065 | - | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges